A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation

OBJECTIVES: Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C). METHODS: This phase 3, double-blind, parallel-group, placebo-controlle...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Satish, Lembo, Anthony J, Shiff, Steven J, Lavins, Bernard J, Currie, Mark G, Jia, Xinwei D, Shi, Kelvin, MacDougall, James E, Shao, James Z, Eng, Paul, Fox, Susan M, Schneier, Harvey A, Kurtz, Caroline B, Johnston, Jeffrey M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Functional GI Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504311/
https://www.ncbi.nlm.nih.gov/pubmed/22986440
http://dx.doi.org/10.1038/ajg.2012.255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504311/
https://www.ncbi.nlm.nih.gov/pubmed/22986440
http://dx.doi.org/10.1038/ajg.2012.255

Ejemplares similares